# Alprostadil Liposomes for Injection for Lower Extremity Arteriosclerosis Obliteran

> **NCT04197323** · PHASE2 · UNKNOWN · sponsor: **CSPC ZhongQi Pharmaceutical Technology Co., Ltd.** · enrollment: 20 (estimated)

## Conditions studied

- Peripheral Artery Disease

## Interventions

- **DRUG:** Alprostadil liposomes for injection

## Key facts

- **NCT ID:** NCT04197323
- **Lead sponsor:** CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-10-01
- **Primary completion:** 2021-06-01
- **Final completion:** 2021-06-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2019-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04197323

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04197323, "Alprostadil Liposomes for Injection for Lower Extremity Arteriosclerosis Obliteran". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04197323. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*